TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06046963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
Description: Sintilimab: 200 mg, intravenous infusion, d1, q3w; Nab-paclitaxel: 100 mg/m2 intraperitoneal infusion, d1, q3w; S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w; Oxaliplatin: 130 mg/m2, intravenous infusion, d1, q3w; The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects wil continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of informed Consent Form, or termination in the investigator's judgment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
Description: Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected at diferent time points (if feasible, according to the samples taken in the standard practice):~at Baseline; After 1-2 cycles of treatment; at the time of the progression or recurrence, if applicable.
Study: NCT05331963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
Study: NCT06507202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: General anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil, and recovered with flumazenil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia is induced and maintained by continuous infusion of propofol and remifentanil.
Study: NCT05373160

Intervention type: OTHER
Intervention: Assessment study
Description: Assessment of functional tests with and without dual tasks
Study: NCT06387368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
Study: NCT05481151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b-njft)
Description: Ropeginterferon alfa-2b-njft

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropeginterferon alfa-2b-njft (P1101)
Description: Ropeginterferon alfa-2b-njft
Study: NCT06491277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flossband
Description: The use of Flossband (Sanctband COMPRE Floss 5.1 cm × 3.5 m; Sanct Japan Co., Ltd.), made of natural rubber, was applied starting from 5 cm below the ankle joint line with a 50% stretch. The band tension was increased to 70-75% around 2 cm above the attachment point of the Achilles tendon.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Controlled Group
Description: Cramer Tape Underwrap (7cm X 27m) foam bandage was applied starting 5 cm below the ankle joint line without tension. The control group received the same exercise protocol as the study group.
Study: NCT04247685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-lead ECG monitoring device (MiRTLE Medical)
Description: 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical is the experimental device;

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3-lead ECG gating system
Description: 3-lead ECG gating system is the placebo/standard of care
Study: NCT04533503

Intervention type: DEVICE
Intervention: HF-OCT Imaging with the Vis-Rx Micro-Imaging Catheter
Description: Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
Study: NCT06347887

Intervention type: DIAGNOSTIC_TEST
Intervention: ColonAiQ test and Colonoscopy
Description: Diagnostic Test

Intervention type: DIAGNOSTIC_TEST
Intervention: ColonAiQ test and Colonoscopy
Description: Diagnostic Test
Study: NCT04710160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel fast-setting calcium silicate cement (Protooth)
Description: In form of power and liquid to be mixed together to form a paste.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novel fast-setting calcium silicate cement (Protooth)
Description: In form of power and liquid to be mixed together to form a paste.
Study: NCT06609694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable oxygen concentrator Inogen G5 model
Description: The concentrator weighs 4.7 lbs. and has a battery life of 13 hours. It has 6 settings with 1 providing the lowest pulse flow and 6 provides the highest flow. The setting will be increased every 30 minutes by 1 when oxygen nadir is lower than 94% and or obstructive index is ≥ 5 /hour.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable oxygen concentrator Inogen G5 model
Description: The concentrator weighs 4.7 lbs. and has a battery life of 13 hours. It has 6 settings with 1 providing the lowest pulse flow and 6 provides the highest flow. The setting will be increased every 30 minutes by 1 when oxygen nadir is lower than 94% and or obstructive index is ≥ 5 /hour.
Study: NCT05077085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Description: single intravenous infusion of bezlotoxumab 10 mg/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin oral
Description: 14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin oral
Description: 14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
Study: NCT04991792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group 1: Infant Formula with synbiotics
Description: Infants will receive infant formula during the first 6 months of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group 2: Infant Formula with prebiotics
Description: Infants will receive infant formula during the first 6 months of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 1 and 2: Infant Formula without synbiotics
Description: Infants will receive infant formula during the first 6 months of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 1 and 2: Infant Formula without synbiotics
Description: Infants will receive infant formula during the first 6 months of life
Study: NCT05162989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCare HOME2 vs iCare IC200
Description: Measurement of IOP with iCare HOME2 compared with iCare IC200.
Study: NCT06300450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Alert
Description: On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease
Study: NCT05389085

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Reflectance confocal microscopy (RCM), Photoacoustic imaging (PAI) and tape-strippng of RNA and lipids
Description: In vivo RCM will be used to diagnose pigmented tumours at a cellular level and provide information on skin microarchitecture. MSOT detects skin chromophores as melanin, hemoglobin, water, collagen, and lipids, which will be included in analysis of diagnostic accuracies. MSOT will also be used to measure tumour thickness; delineate tumour borders and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. RNA and lipid profiles from tape stripping results will be compared to imaging and histopathology diagnosis.
Study: NCT05921825

Intervention type: DIAGNOSTIC_TEST
Intervention: Red cell distribution width
Description: Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis

Intervention type: DIAGNOSTIC_TEST
Intervention: Red cell distribution width
Description: Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis

Intervention type: DIAGNOSTIC_TEST
Intervention: lactate albumin ratio measurement
Description: Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis

Intervention type: DIAGNOSTIC_TEST
Intervention: lactate albumin ratio measurement
Description: Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
Study: NCT04714931

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sentinel lymph node detection
Description: Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
Study: NCT05240820

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multi-layer wound closure
Description: We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: multi-layer wound closure
Description: We prospectively analyze clinical outcome data from 30 subjects who perform multi-layer wound closure using polyglactin 910 and polypropylene, and polydioxanone and combination of 2-octyl cyanoacrylate and polyester mesh following excision of giant benign tumors.
Study: NCT04546711

Intervention type: OTHER
Intervention: Ketogenic Diet
Description: The ketogenic diet (KD) is a high fat, very low carbohydrate diet
Study: NCT01529892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single oral 5 mg of duterium labeled methamphetamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A single oral 5 mg of duterium labeled methamphetamine
Study: NCT06297369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N acetyl cysteine
Description: N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)
Study: NCT04829201

Intervention type: PROCEDURE
Intervention: functional septorhinoplasty or oropharyngeal/orthognathic surgery
Description: obtain pre- and postoperative data in order to describe the specific changes in airflow and upper soft tissue behavior that causes sleep apnea
Study: NCT04992312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon Nasal Powder [Baqsimi]
Description: Administered intranasally
Study: NCT06071078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training of professionals according to the DISCUSS announcement protocol
Description: The emergency services will be divided into 4 clusters (2 or 3 services per cluster). Each cluster will belong successively to the control arm and then to the intervention arm according to a 5 successive steps of 4 months duration (stepped wedge method). The deployment of the training will therefore not be done simultaneously in the different services.~Individuals in this group will have received a decision of withholding and withdrawing life-sustaining treatments according to the DISCUSS announcement protocol, by a professional trained in this procedure.
Study: NCT04764071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotomy
Description: percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 30F.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultra-mini percutaneous nephrolithotomy
Description: percutaneous access of the desired calyx is achieved under fluoroscopic guidance with the use of an 18-gauge needle and a guidewire passage. Tract dilation is accomplished by using Amplatz dilators up to 12-14 F fascial dilator was used to dilate the nephrostomy tract to pass the 13 F semi-rigid plastic sheath.
Study: NCT05577507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine Resin 4000 MG [Questran]
Description: cholestyramine 4 gram sachets (questran) will be administered orally three times daily for 8 weeks period trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate 500 MG Oral Tablet
Description: control group will administer standard therapy calcimate 500 mg three times daily within meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate 500 MG Oral Tablet
Description: control group will administer standard therapy calcimate 500 mg three times daily within meals
Study: NCT04552652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Remotely monitored exercises will be performed at home. The high-intensity interval group warms-up for 5 minutes at moderate intensity (65-75% of maximal heart rate). After warm-up exercise, will continue in 4 minutes intervals at high-intensity to reach the target zone (85-95% of maximal heart rate) Each interval will be separated by 3 minutes of active recoveries (at 65-75% of maximal heart rate). The session ends with a 3-minute cool-down phase. Overall training exercise time will be 33 minutes - isocaloric compared to moderate-intensity continous training group. All participants will train using a heart rate monitor during each workout.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: Remotely monitored exercises will be performed at home. Patients in the moderate-intensity continuous training group will perform a 41-minute constant workout with an intensity of 65-75% of maximum heart rate, representing the same total training load as the high-intensity aerobic exercise group. All participants will train using a heart rate monitor during each workout.
Study: NCT05121064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention
Description: The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention
Description: The alcohol brief intervention (BI) was based on CETA'S substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring possibilities of change, goal setting, identifying reasons for alcohol use and skill building) including a 2-week alcohol timeline follow back assessment completed by provider. The alcohol brief intervention (BI) will be conducted by a trained counselor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: CETA is a multisession cognitive behavioral therapy (CBT)-based model. CETA consists of elements: engagement, safety assessment, psychoeducation, substance use reduction, behavioral activation, cognitive coping, relaxation, exposure and problem solving. During a weekly clinic meeting, newly enrolled participants who are assigned to get CETA will be assigned to a specific counselor. The counsellor, together with their supervisor, will design an individualized treatment plan including type and order of Common Elements Treatment Approach (CETA) for each participant. The counsellor will contact participants by phone or home visit to schedule CETA session. CETA sessions will begin with standardized clinical monitoring form to track progress of treatment and each session will last 45-90 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care (SOC) at HIV clinics in Zambia consist of Antiretroviral Treatment (ART) adherence counselling. All participants will receive Standard of Care (SOC), but for participants in Arm C it will be the only alcohol treatment. The ART adherence counseling includes brief unstructured discussion of substance use and mental health issues with a focus on issues that reduce adherence and retention issues. ART adherence counseling is delivered in a one-on-one format between patient and counsellor and it usually lasts 5-10 minutes.
Study: NCT03787511

Intervention type: OTHER
Group type: OTHER
Intervention: Cough assessment
Description: Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough

Intervention type: OTHER
Group type: OTHER
Intervention: Cough assessment
Description: Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological tests and cardiovascular tests
Description: Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough

Intervention type: OTHER
Group type: OTHER
Intervention: Neurological tests and cardiovascular tests
Description: Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough

Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
Study: NCT06582927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Attention Training (MBAT)
Description: MBAT is an evidence-based program that comprises 4, 2-hour sessions virtual delivered across 4 consecutive weeks.~The 4 sessions correspond to 4 central topics and associated practices. The concentration topic introduces participants to mindfulness basics, including discussion of focused attention and mind wandering. The body awareness theme involves the cultivation of greater self-awareness, and the development of equanimity. The open monitoring theme emphasizes awareness of and receptivity to changing experiences and moments of uncertainty. The theme of connection addresses leadership and group cohesion, and the cultivation of kindness and connection with others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Attention Training (MBAT)
Description: MBAT is an evidence-based program that comprises 4, 2-hour sessions virtual delivered across 4 consecutive weeks.~The 4 sessions correspond to 4 central topics and associated practices. The concentration topic introduces participants to mindfulness basics, including discussion of focused attention and mind wandering. The body awareness theme involves the cultivation of greater self-awareness, and the development of equanimity. The open monitoring theme emphasizes awareness of and receptivity to changing experiences and moments of uncertainty. The theme of connection addresses leadership and group cohesion, and the cultivation of kindness and connection with others.
Study: NCT05186194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D, Calcium
Description: Vitamin D, calcium are available in tablets. During the 8 weeks of training, subjects were asked to take supplement tablets per day after dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06372873

Intervention type: OTHER
Intervention: re-evaluate by two senior radiologists in our medical center
Description: The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center

Intervention type: OTHER
Intervention: re-evaluate by two senior radiologists in our medical center
Description: The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center

Intervention type: OTHER
Intervention: re-evaluate by two senior radiologists in our medical center
Description: The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center

Intervention type: OTHER
Intervention: re-evaluate by two senior radiologists in our medical center
Description: The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center
Study: NCT06243393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (SG)
Description: Treatment with Sacituzumab Govitecan (SG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physicians Choice (PhC).
Description: Treatment according to oncologic guidelines.
Study: NCT05773664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of cavity fluid and blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of cavity fluid and blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging of the Brain with and without Contrast
Description: Undergo MRI with or without contrast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging of the Brain with and without Contrast
Description: Undergo MRI with or without contrast